China Traditional Chinese Medicine Holdings (0570) Fundamentals 2026 — Revenue Analysis | SniperIQ
China Traditional Chinese Medicine Holdings (0570) is a HK-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of HK$7.0B, trading at HK
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is China Traditional Chinese Medicine Holdings's market cap?
China Traditional Chinese Medicine Holdings (0570) has a market capitalization of approximately HK$7.0B, trading at HK
What is China Traditional Chinese Medicine Holdings's P/E ratio?
China Traditional Chinese Medicine Holdings's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is China Traditional Chinese Medicine Holdings?
China Traditional Chinese Medicine Holdings runs a net profit margin of -2.3%, a gross margin of 48.1%, and an operating margin of -1.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does China Traditional Chinese Medicine Holdings generate?
China Traditional Chinese Medicine Holdings reported revenue of ¥14.7B for fiscal year 2025, with net income of -¥342M and earnings per share (EPS) of -0.0679. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does China Traditional Chinese Medicine Holdings pay a dividend?
China Traditional Chinese Medicine Holdings offers a trailing dividend yield of about 6.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is China Traditional Chinese Medicine Holdings financially healthy?
China Traditional Chinese Medicine Holdings carries a debt-to-equity ratio of 0.12x and a current ratio of 2.29x, with a market beta of 0.73. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is China Traditional Chinese Medicine Holdings a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For China Traditional Chinese Medicine Holdings (0570) the key facts are: market cap HK$7.0B, revenue ¥14.7B, 52-week range 1.32-2.68. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track China Traditional Chinese Medicine Holdings's full fundamentals live
Get China Traditional Chinese Medicine Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.